FACT SHEET

MANULIFE DANA EKUITAS INDONESIA CHINA - USD

Investment Objective

To generate capital appreciation by investing in medium to long term in Indonesian equities and/or companies listed on the Hong Kong stock exchange (including China Hshares and red chip companies) that derive majority of their revenue from China.

Fund Information


Inception Date USD 0.1141 Inception Price Fund Size USD 8.772.513.56 Number of unit 80 318 380 87 Net Asset Value/Unit 4) USD 0.1092 Fund Currency LISD Type of fund Equity Valuation Daily

Custodian Bank Standard Chartered Bank

Annual Management Fee 2.50% Bloomberg Code MLLDECU IJ

Fund Manager PT Manulife Aset Manajemen Indonesia

Risk Classification



Note

- Annualized (1 year = 365 days) and using compound method (for products that have been more than one year old since inception).
- 2) The benchmark is 85% JCI + 15% Hang Seng Mainland 25 Index in USD terms.
- 3) Based on GICS (Global Industrials Classification Standard)
- The Net Asset Value / Unit has calculated the costs, including settlement as well as administration and recording.

Performance Since Inception

Monthly Performance Last 3 Years





Performance in USD per (30/04/25)												
	1 mo	3 mo	6 mo	YTD	1 yr	3 yr ¹⁾	5 yr ¹⁾	Since Inception 1)				
MDEIC (in USD)	2.19%	-2.72%	-10.28%	-3.60%	-0.44%	-16.58%	5.78%	-0.29%				

2.36% -3.80% -11.29% -3.80% -2.45% -3.81% 5.05% 1.73%

Yearly Performance												
	2024	2023	2022	2021	2020	2019	2018	2017				
MDEIC (in USD)	-8.28%	-13.28%	-18.70%	38.05%	2.94%	3.43%	-14.00%	15.40%				
BM 2)	-1.84%	4.10%	-5.48%	4.51%	-5.26%	7.47%	-9.77%	21.71%				

Top Holdings* & Sector Allocation3

Time Deposit - Bank Tabungan Negara Stock - Aneka Tambang Tbk

Stock - Bank Central Asia Tbk PT Stock - Bank Mandiri Persero Tbk PT

Stock - Bank Negara Indonesia Persero Tbk PT

Stock - Bank of China Ltd

Stock - Bank Pan Indonesia Tbk PT

Stock - Bank Rakvat Indonesia Persero Tbk PT

Stock - Bank Svariah Indonesia Tbk PT

Stock - Bundamedik Tbk PT

Stock - BYD Co Ltd

BM 2)

Stock - Chandra Asri Pacific Tbk PT

Stock - GoTo Gojek Tokopedia Tbk PT

Stock - Hillcon Tbk PT

Stock - Impack Pratama Industri Tbk PT

Stock - Indofood CBP Sukses Makmur Tbk PT

Stock - Indofood Sukses Makmur Tbk PT

Stock - Indosat Tbk PT

Stock - Jasa Marga Persero Tbk PT


Stock - Mayora Indah Tbk PT

Stock - Panin Financial Tbk PT

Stock - Telkom Indonesia Persero Tbk PT Stock - Tencent Holdings Ltd

Stock - Triputra Agro Persada PT

Stock - Xiaomi Corp



Investment Manager Commentary

April was a volatile period for the market, where early in the month the market was surprised by US reciprocal tariff announcement that are bigger than expected. However market sentiment improved opinions a volume period on the manket, where early in the manket was surprised by OS teclprical and manufacturent that are bugget that expected. However market seliminate represents in the properties of following US decision to postpone the tariff for 90 days, allowing time for negotiations. The market also welcomed the decision to relax tariffs on several sectors (electronics and automotive), while optimism on positive trade negotiation continue to drove the market higher. On the domestic front, improvement of state budget position is a positive sentiment, especially on improvement in tax revenue. The finance minister also stated that budget reallocation process is concluded and the government will focus on policy implementation. GDP growth for 1Q-2025 fell to 4.87% from 5.02% in 4Q-2021 feel. 2024. Growth was weighed by weaker household consumption, government spending, and investment. Meanwhile, Bank Indonesia maintained BI Rate at 5.75% in April, emphasizing that policy focus is on Rupiah stability. Chinese equities were weaker in April overshadowed by higher tariffs between US and China. Portfolio allocations in consumer staples contributed positive attributions, meanwhile allocations in materials contributed negative attributions to performance.

Disclaimer: This report is prepared by PT Asuransi Jiwa Manulife Indonesia only for information purposes and not to be used as a sales offering or proposal. Although this report has been prepared meticulously, PT Asuransi Jiwa Manulife Indonesia does not guarantee its accuracy, sufficiency or completeness, and is not responsible for any consequences arising from any actions which are based on the information stated herein. Investments in capital market instruments are subject to various risks which include, but not limited to, market risk, interest rate risk, exchange rate risk (particularly in Fund which has allocation in offshore investments in different currencies than the Fund's currency), liquidity risk and other risks which could result in performance volatility. Therefore, the performance of this Fund is not guaranteed, the unit price of each Fund may go up or down and past performance does not necessarily indicative of future performance.









